Ernexa Therapeutics Inc (ERNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Sales | 582 | 68 | 0 | 0 | 0 |
| Cost of Goods | 96 | 236 | 0 | N/A | N/A |
| Gross Profit | 486 | -168 | N/A | N/A | N/A |
| Operating Expenses | 16,256 | 21,203 | 33,217 | 113,732 | 7,248 |
| Operating Income | -15,674 | -21,135 | -33,217 | -113,732 | -7,248 |
| Interest Expense | 6,752 | 614 | 30 | 0 | 0 |
| Other Income | -22,083 | 78 | 8,713 | -8,749 | -43 |
| Pre-tax Income | -44,509 | -21,671 | -24,534 | -122,481 | -7,291 |
| Income Tax | 30 | -3 | 45 | 64 | 0 |
| Net Income Continuous | -44,539 | -21,668 | -24,579 | -122,545 | -7,291 |
| Net Income | $-44,539 | $-21,668 | $-24,579 | $-122,545 | $-7,291 |
| EPS Basic Total Ops | -48.88 | -61.17 | -120.84 | -848.73 | -122.94 |
| EPS Basic Continuous Ops | -48.93 | -61.13 | -120.78 | -848.62 | -124.30 |
| EPS Diluted Total Ops | -48.88 | -61.17 | -120.84 | -848.73 | -122.94 |
| EPS Diluted Continuous Ops | -48.93 | -61.13 | -120.78 | -848.62 | -124.30 |
| EPS Diluted Before Non-Recurring Items | -48.88 | -61.17 | -120.84 | -368.82 | -719.64 |
| EBITDA(a) | $-8,777 | $-19,709 | $-32,720 | $-113,273 | $-7,150 |